Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.52 |
| ▸ | RELA | Q04206 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5775 | 0.82 | LTA4H (0.51) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL13841588 | 0.82 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL1674237 | 0.80 | SMN1; SMN2 (0.62) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| Ammonia Solution, Strong SCHEMBL28862490 | 0.80 | LTA4H (0.50) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL5043401 | 0.80 | SMN1; SMN2 (0.46) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL2611134 | 0.80 | KMT2A (0.54) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL5774 | 0.80 | SMN1; SMN2 (0.46) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL2644715 | 0.80 | SMN1; SMN2 (0.46) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL2611131 | 0.80 | LMNA (0.49) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL8137879 | 0.80 | SMN1; SMN2 (0.46) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3773552-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2021-02-17 | — | — | EP | claimed |
| WO-2019191229-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. (US) | 2019-10-03 | — | — | WO | claimed |
| EP-1702919-B1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | MSD KK (JP) | 2012-05-30 | — | — | EP | claimed |
| US-20230331725-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11780839-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-9149465-B2 | Isoxazolines as inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140256756-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2014-09-11 | — | — | US | disclosed |
| EP-1810969-B1 | ARYLOXY-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | MSD KK (JP) | 2013-08-07 | — | — | EP | disclosed |
| WO-2013066869-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| EP-1702919-B1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | MSD KK (JP) | 2012-05-30 | — | — | EP | disclosed |
| CN-102459202-A | Isoxazolines as inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS INC | 2012-05-16 | — | — | CN | disclosed |
| WO-1995031439-A1 | THERAPEUTIC PHENOXYALKYLPYRIDAZINES AND INTERMEDIATES THEREFOR | SANOFI WINTHROP, INC. (US) | 1995-11-23 | — | — | WO | disclosed |
| WO-1995031452-A1 | THERAPEUTIC PHENOXYALKYLAZOLES AND PHENOXYALKYLAZINES | SANOFI WINTHROP, INC. (US) | 1995-11-23 | — | — | WO | disclosed |
| US-5364865-A | Phenoxy- and phenoxyalkyl-piperidines as antiviral agents | STERLING WINTHROP INC. (US) | 1994-11-15 | — | — | US | disclosed |
| EP-0605031-A1 | Phenoxy- and phenoxyalkyl-piperidines as antiviral agents | STERLING WINTHROP INC. (US) | 1994-07-06 | — | — | EP | disclosed |
| EP-0577217-A1 | Tetrazolyl-(phenoxy and phenoxyalkyl) piperidininylpyridazines as antiviral agents | STERLING WINTHROP INC. (US) | 1994-01-05 | — | — | EP | disclosed |
| US-5242924-A | Tetrazolyl-(phenoxy and phenoxyalkyl)-piperidinylpyridazines as antiviral agents | STERLING WINTHROP INC. (US) | 1993-09-07 | — | — | US | disclosed |
| EP-0039892-B1 | SUBSTITUTED PHENYL ETHERS | CIBA-GEIGY AG (CH) | 1986-12-30 | — | — | EP | disclosed |
| US-4559354-A | ADRENERGIC BLOCKING AGENTS AND STIMULANTS; CARDIOTONIC, ANTIARRHYTHMIA AND INOTROPIC AGENTS | CIBA-GEIGY CORPORATION (US) | 1985-12-17 | — | — | US | disclosed |
| EP-0039892-A1 | Substituted phenyl ethers | CIBA-GEIGY AG (CH) | 1981-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256756-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | GPR119, GPR139, GLP1R | NPC1 1196/4885RAB9A 646/4885SMN1; SMN2 3196/4885 |
| US-20230331725-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, HDAC6 | NPC1 83/4885RAB9A 1498/4885SMN1; SMN2 84/4885 |
| US-11780839-B2 | Compounds for treating Huntington's disease | HTT, HYPK, HDAC6 | NPC1 83/4885RAB9A 1498/4885SMN1; SMN2 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.